Iron saccharate

• CAS: 8047-67-4
• Catalog Number: ACM8047674
• Category: Main Products
• Molecular Weight: 398.14
• Molecular Formula: C18H24Fe2O24
• Description: Iron Saccharate has been used to treat iron deficiency and iron deficiency anemia associated with different chronic diseases.
• Synonyms: ferrivenin;Sucrofer;Fesin;Hippiron
• IUPAC Name: iron(3+);(2R,3S,4S,5S)-2,3,4,5-tetrahydroxyhexanedioate
• SMILES: C(C(C(C(=O)[O-])O)O)(C(C(=O)[O-])O)O.C(C(C(C(=O)[O-])O)O)(C(C(=O)[O-])O)O.C(C(C(C(=O)[O-])O)O)(C(C(=O)[O-])O)O.[Fe+3].[Fe+3]
• InChI Key: ADQSUDSYBZBMFT-GFPJEPEZSA-H
• Boiling Point: 766.4ºC at 760 mmHg
• Melting Point: MORE THAN 51ºC
• Flash Point: 431.2ºC
• Appearance: brown powder
• EC Number: 232-464-7
• Exact Mass: 735.93600
• HS Code: 3004909090
• LogP: -18.21560
• PSA: 483.54

Case Study

Iron Saccharate as an Intravenous Iron Supplement for Renal Anaemia in Haemodialysis Patients

Cui, Hong-Xia, et al. Tropical Journal of Pharmaceutical Research 15.10 (2016): 2269-2274.

Iron saccharate is a colloidal iron(III) hydroxide-sucrose complex used to correct iron deficiency in patients with renal anaemia undergoing haemodialysis. When administered together with erythropoietin (EPO), it effectively raises haemoglobin and iron storage parameters, but may exacerbate oxidative stress. Combination with levocarnitine can mitigate this pro-oxidant effect and improve therapeutic outcomes.
Study Protocol: A randomised controlled trial enrolled 156 patients with renal anaemia undergoing maintenance haemodialysis. The control group (n = 78) received subcutaneous EPO (150-200 U/kg, dose adjusted according to haemoglobin levels) plus intravenous iron saccharate (100 mg after each dialysis session) for 28 weeks. The test group (n = 78) received the same regimen plus intravenous levocarnitine (1.0 g after each dialysis). Anaemia indices (haemoglobin, haematocrit, serum ferritin, transferrin saturation) and oxidative stress markers (advanced oxidation protein products, malondialdehyde) were measured at baseline and week 28.
Performance Evaluation: In the control group (iron saccharate alone), haemoglobin increased from baseline to 92.72 ± 12.51 g/L at week 28, while oxidative stress markers rose significantly (AOPP: 89.65 ± 30.53 mmol/L; MDA: 4.81 ± 2.57 mmol/L). In the test group (iron saccharate plus levocarnitine), haemoglobin reached 114.36 ± 12.27 g/L (p < 0.05 vs. control), and oxidative stress markers were markedly lower (AOPP: 121.77 ± 31.65 mmol/L; MDA: 9.58 ± 2.64 mmol/L; p < 0.05). The response rate was higher (92.3% vs. 76.9%), and the required EPO dose was reduced in the combination group.

Iron Saccharate as a Well-Tolerated Oral Iron Supplement in Healthy Premenopausal Women

Friling, Marina, et al. International Journal of Molecular Sciences 23.20 (2022): 12282.

Iron saccharate, when formulated as a microencapsulated ferric saccharate (MFS) product, offers improved gastrointestinal tolerability compared with conventional ferrous sulphate (FS). This makes it a promising alternative for oral iron supplementation, particularly in women of reproductive age who are at risk of iron deficiency but often discontinue treatment due to side effects.
Study Protocol: A randomised, double-blind, two-way crossover trial enrolled 47 healthy premenopausal women (mean age 30.7 years, ferritin 30.5 μg/L). Each participant received either MFS (60 mg elemental iron/day as ferric saccharate) or FS (60 mg/day) for 14 consecutive days, separated by a washout period of two menstrual cycles (minimum one month). A daily questionnaire recorded 10 predefined symptoms with intensity scales and duration. The washout period served as a real-life reference (no iron supplementation).
Performance Evaluation: The percentage of participants experiencing at least one symptom was significantly lower with MFS than with FS (72.3% vs. 91.5%). MFS caused fewer gastrointestinal complaints (68.1% vs. 87.2%), particularly nausea (8.5% vs. 23.4%), abdominal pain (21.3% vs. 36.2%), flatulence/swelling (42.6% vs. 63.8%) and diarrhoea (12.8% vs. 29.8%). The total number of complaints and symptom intensity were also significantly lower for MFS. No serious adverse events occurred. Iron parameters remained within normal ranges for both products.
Microencapsulated iron saccharate is significantly better tolerated than ferrous sulphate at the same elemental iron dose, with fewer and less severe gastrointestinal side effects. It provides a safe and effective option for oral iron supplementation.

Custom Q&A

What is the molecular formula of Iron saccharate?

The molecular formula of Iron saccharate is C18H24Fe2O24.

What is the synonym for Iron saccharate?

The synonym for Iron saccharate is iron(3+);(2S,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanedioate.

What is the molecular weight of Iron saccharate?

The molecular weight of Iron saccharate is 736.1 g/mol.

What is the parent compound of Iron saccharate?

The parent compound of Iron saccharate is Glucaric acid.

What is the medical use of Iron saccharate?

Iron saccharate is used in the treatment of iron-deficiency anemia, including in patients with chronic kidney disease, when oral iron therapy is ineffective or impractical.

What is the IUPAC name of Iron saccharate?

The IUPAC name of Iron saccharate is iron(3+);(2S,3S,4S,5R)-2,3,4,5-tetrahydroxyhexanedioate.

What is the InChI of Iron saccharate?

The InChI of Iron saccharate is InChI=1S/3C6H10O8.2Fe/c3*7-1(3(9)5(11)12)2(8)4(10)6(13)14;;/h3*1-4,7-10H,(H,11,12)(H,13,14);;/q;;;2*+3/p-6/t3*1-,2-,3-,4+;;/m000../s1.

What is the InChIKey of Iron saccharate?

The InChIKey of Iron saccharate is ADQSUDSYBZBMFT-GFPJEPEZSA-H.

What is the CAS number of Iron saccharate?

The CAS number of Iron saccharate is 8047-67-4.

What is the hydrogen bond donor count of Iron saccharate?

The hydrogen bond donor count of Iron saccharate is 12.